Dr Akira Andoh and colleagues from Japan analyzed the fecal microbiota profiles of patients with Crohn’s disease at 4 inflammatory bowel disease centers located in different districts in Japan.
Terminal restriction fragment length polymorphism analysis was performed in 161 fecal samples from Crohn’s disease patients, and 121 samples from healthy individuals.
The team of doctors found evaluated the bacterial diversity by the Shannon diversity index.
There were no regional differences in the fecal microbiota profiles of the healthy individuals in Japan.
The researchers investigated that a setting of similarity generated 3 major clusters of terminal restriction fragments.
Group 1 included almost all the healthy individuals, and Groups 2 and 3 were mainly formed by Crohn’s disease patients at different stages of disease activity.
|The genus Bifidobacterium was decreased during the active phase of Crohn’s |
|Journal of Gastroenterology|
The changes in simulated bacterial composition indicated that the class Clostridia, including the genus Faecalibacterium, was significantly decreased in Crohn’s disease patients with active disease and those in remission as compared with findings in the healthy individuals.
The doctors found that in contrast, the genus Bacteroides was significantly increased in Crohn’s disease patients during the active phase as compared with findings in the healthy individuals.
The genus Bifidobacterium was significantly decreased during the active phase of Crohn’s disease and increased to healthy levels during the remission phase.
With the outcomes of the study the researchers found that the bacterial diversity measured by the SDI was significantly reduced in Crohn’s disease patients during the active and remission phases as compared with findings in the healthy individuals.
From the clinical data and terminal-restriction fragment length polymorphism analysis, we developed a logistic model to predict disease activity based on the fecal microbiota composition.
Andoh and his team concluded "Dysbiosis in Crohn’s disease patients was shown by a multi-IBD center study."
"The feasibility of using the fecal microbiota profile as a predictive marker for disease activity is proposed."